Patent 5,412,095 protects and is included in zero NDA.
|Title:||Terazosin monohydrochloride and processes and intermediate for its production|
|Abstract:||The present invention provides a non-solvated crystalline polymorph of terazosin monohydrochloride designated Form III and methods for its preparation. Also disclosed is terazosin monohydrochloride methanolate and processes for its production as well as processes for its conversion to other crystalline forms of terazosin monohydrochloride.|
|Inventor(s):||Morley; James A. (Gurnee, IL), Bauer; John F. (Lake Bluff, IL), Patel; Ramesh F. (Chicago, IL), Henry; Rodger E. (Waukegan, IL), Spanton; Stephen G. (Grayslake, IL)|
|Assignee:||Abbott Laboratories (Abbott Park, IL)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Publication Date|
|United States of America||5294615||Mar 15, 1994|
|United States of America||5362730||Nov 08, 1994|
|United States of America||5947723||Sep 07, 1999|
|Mexico||9306196||Jan 31, 1994|
|Japan||6312984||Nov 08, 1994|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.